C3898689_NCI_CareLex | Knowledge4COVID-19

Property	Value
?:definition	A document that confirms identity, purity, and strength of the investigational product(s) (IP) to be used in the clinical trial is in accordance with the specifications of the IP, and includes the acceptance limits and the actual test results. [Adapted from TMF-RM]
?:hasCUIAnnotation	<https://research.tib.eu/covid-19/entity/C3898689>
?:hasGeneratedBy	<https://research.tib.eu/covid-19/SourceName/NCI_CareLex>
?:type	<https://research.tib.eu/covid-19/vocab/AnnotationDefinition>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/C3898689_NCI_CareLex>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/C3898689_NCI_CareLex>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all